MINNEAPOLIS, Oct. 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, November 5, 2025, at 8:00 a.m. CST to review its first quarter fiscal 2026 financial results.
Access to the discussion may be obtained as follows:
Time: | 8:00 a.m. CST |
Date: | November 5, 2025 |
Dial-in: | 1-800-274-8461 or 1-203-518-9814 (for international callers) |
Conference ID: | TECHQ1 |
Webcast: |
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 11160247.
The replay will be available from 11:00 a.m. CST on Wednesday, November 5, 2025, until 11:00 p.m. CST on Friday, December 5, 2025.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at LinkedIn, X, or YouTube.
Contact:
David Clair, Vice President, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
612-656-4416
| Last Trade: | US$61.68 |
| Daily Change: | -1.86 -2.93 |
| Daily Volume: | 1,430,402 |
| Market Cap: | US$9.610B |
November 25, 2025 November 18, 2025 November 06, 2025 November 05, 2025 November 04, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
